Medicare's $50 GLP-1 Program, an Altered Drug Trial & Cyclospora's 18-State Spread
Key Takeaways
- Medicare has launched a new bridge program providing eligible Part D beneficiaries access to GLP-1 medications like Wegovy and Zepbound for a $50 monthly copay through the end of 2027.
- The Advocate trial for the drug avacopan (Tavneos) has been retracted after FDA reviewers discovered significant data integrity issues, including unblinded and altered datasets.
- A Cyclospora outbreak has expanded to 18 states, highlighting the challenge that standard produce washing is ineffective at removing this specific parasite.
- Alibaba has reached a $600 million settlement regarding the supply of fentanyl precursors, marking a significant development in the international effort to combat the opioid crisis.
- The WHO has issued its first emergency-use approval for a diagnostic test targeting the Bundibugyo strain of the Ebola virus.
Friday, July 10, 2026
In today's episode, Dr. Will Flanary / Dr. Glaucomflecken (@drglaucomflecken) & Eva Johnson cover the retraction of the Advocate trial after FDA reviewers found the avacopan (Tavneos) dataset was unblinded, re-adjudicated, and altered before being relocked, throwing its approval for ANCA-associated vasculitis into doubt. They break down Medicare's new GLP-1 Bridge program, which offers eligible Part D beneficiaries drugs like Wegovy and Zepbound at $50 a month through the end of 2027, and why that copay sits outside normal Part D accounting. They also track a Cyclospora outbreak now reported across 18 states and why routine washing does not reliably kill it. Plus: they also discuss Alibaba's $600 million fentanyl-precursor settlement, the WHO's first emergency-use Ebola (Bundibugyo) diagnostic, France's deadly heat wave, and more.
Coverage Timeline:
(00:00) Intro
(01:04) Vasculitis Trial Retracted:
(03:44) Medicare’s GLP‑1 Bridge
(06:02) Parasite, Ebola, Heat Wave
Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com.
Sources & Media Attributions for Today's Episode Available At:
Medlines is a Human Content Production
Frequently Asked Questions
What is the new GLP-1 Medicare coverage bridge program?
The Medicare GLP-1 Bridge program allows eligible Part D beneficiaries to obtain specific GLP-1 weight-loss medications for a flat $50 monthly copay through the end of 2027.
Why was the Advocate clinical trial for avacopan retracted?
The trial was retracted after FDA reviewers found that the avacopan (Tavneos) dataset had been unblinded and altered, compromising the validity of the approval data for ANCA-associated vasculitis.
How do you prevent Cyclospora infection from fresh produce?
Unfortunately, routine washing of fruits and vegetables does not reliably kill or remove Cyclospora, making it a persistent risk in current outbreaks across 18 states.